Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in Grifols, S.A. (NASDAQ:GRFS) by 56.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 110,532 shares of the biotechnology company’s stock after acquiring an additional 39,733 shares during the period. Geode Capital Management LLC’s holdings in Grifols were worth $982,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Grifols by 49.4% in the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 1,135 shares during the last quarter. Signaturefd LLC grew its stake in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,153 shares during the last quarter. AQR Capital Management LLC acquired a new position in Grifols during the second quarter worth approximately $89,000. HighTower Advisors LLC lifted its stake in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,546 shares during the last quarter. Finally, Chesapeake Capital Corp IL acquired a new stake in shares of Grifols in the third quarter valued at approximately $148,000.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Down 4.1 %

NASDAQ:GRFS opened at $7.29 on Friday. The stock’s 50 day simple moving average is $8.08 and its 200-day simple moving average is $8.16. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $9.96. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The firm has a market cap of $5.01 billion, a P/E ratio of 5.98 and a beta of 0.41.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.